J&J CFO Wolk on First-Quarter, Vaccine Guidance, Forecast

The transcript covers Johnson & Johnson's performance, highlighting growth in Med Tech and pharmaceuticals, and challenges in consumer health. It discusses the impact of foreign exchange on financials, adjustments in vaccine demand, and global risks like China's lockdowns and the Ukraine war. The resilience of healthcare during potential recessions is also explored.

Which segment led the growth for Johnson & Johnson in the recent quarter?

• Beauty and Skin Health

• Med Tech

• Pharmaceuticals

• Consumer Health

What was the estimated financial impact of FX on Johnson & Johnson's top line for the quarter?

• $3 billion

• $600 million

• $1 billion

• $2.5 billion

How did Johnson & Johnson respond to the global surplus of vaccine supply?

• Increased production

• Focused on M RNA technology

• Stopped vaccine development

• Reduced guidance specificity

What is Johnson & Johnson's current focus in terms of product development?

• Expanding consumer health

• Enhancing general surgery tools

• Developing new vaccine platforms

• Increasing beauty product lines

What was a significant factor affecting Johnson & Johnson's business in China during Q1?

• Currency fluctuations

• Increased competition

• Lockdowns affecting Med Tech

• New product launches

How does Johnson & Johnson view the importance of healthcare in the context of a potential recession?

• As a low priority

• As a minor concern

• As recession-proof

• As critically important

What has the pandemic taught about the importance of healthcare according to Johnson & Johnson?

• It is not a priority for innovation

• It is only important during pandemics

• It is crucial for economic stability

• It is less important than before